Tag Archives: Boston

Anti-Restenotic Drug Delivery with the AGENT Drug-Coated Balloon: Interview with Dr. Ian Meredith, Global CMO, Boston Scientific

Boston Scientific recently announced a clinical trial of its AGENT drug coated balloon. The device is coated with paclitaxel, an anti-restenotic drug, and aims to deliver the medication to the affected vessel wall during a percutaneous procedure. Coronary in-stent restenosis (ISR) is caused by occlusive scar tissue that develops in the stented portion of a… Read More »